Etripamil

INN name:	Etripamil
Lab codes:	find at Durgspider
Chemical name:	methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)- 5-methylhexyl](methyl)amino}ethyl)benzoate
Molecular formula:	C27H36N2O4
Chemical Structure:
CAS Registry Number:	1593673-23-4
Originator:	Milestone Pharmaceuticals
Class:	Antiarrhythmics
Mechanism of Action:	Calcium channel antagonists
WHO ATC code:	C01 (Cardiac Therapy) C01B (Antiarrhythmics, Class I and III)
EPhMRA code:	C1 (Cardiac Therapy) C1B (Anti-Arrhythmics)
Clinical Trials: Conditions Phases Status Paroxysmal Supraventricular Tachycardia (PSVT) Phase 2 Recruiting
Recent activities on the drug:

Guadecitabine

INN name:	Guadecitabine
Lab codes:	Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110
Chemical name:	2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine
Molecular formula:	C18H24N9O10P
Chemical Structure:
CAS Registry Number:	929901-49-5
Originator:	SuperGen
Developer:	Astex Pharmaceuticals; Groupe Francophone des Myelodysplasies
Class:	Antineoplastics
Mechanism of Action:	Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
WHO ATC code:	L01B (Antimetabolites)
EPhMRA code:	L1B (Antimetabolites)
Clinical Trials: Conditions Phases Status Leukemia, Myeloid, Acute Phase 3 Recruiting Non-small Cell Lung Cancer Phase 2 Completed MDS Phase 2 Recruiting Hepatocellular Carcinoma Phase 2 Active, not recruiting Previously Treated Metastatic Colorectal Cancer Phase 1 / Phase 2 Recruiting MDS;   CMML;   AML Phase 1 / Phase 2 Active, not recruiting Ovarian Cancer Phase 1 / Phase 2 Active, not recruiting Germ Cell Tumor Phase 1 Recruiting Metastatic Colorectal Cancer Phase 1 Recruiting Acute Myeloid Leukemia Phase 1 Recruiting
Recent activities on the drug:

Motolimod

INN name:	Motolimod
Lab codes:	VTX-2337
Chemical name:	2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
Molecular formula:	C28H34N4O2
Chemical Structure:
CAS Registry Number:	926927-61-9
Originator:	Array BioPharma
Developer:	VentiRx Pharmaceuticals
Class:	Antineoplastics, immunomodulator
Mechanism of Action:	Toll-like receptor 8 (TLR8) agonist
WHO ATC code:	L03A-X
EPhMRA code:	L3A9
Clinical Trials: Conditions Phases Interventions Recruitment Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Phase 2 Combination Active, not recruiting Carcinoma, Squamous Cell of Head and Neck Phase 2 Combination Active, not recruiting Ovarian Cancer Phase 1|Phase 2 Combination Not yet recruiting Low Grade B Cell Lymphoma Phase 1|Phase 2 Combination Terminated  Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Phase 1 Combination Completed Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Phase 1 Combination Completed Squamous Cell Carcinoma of the Head and Neck Phase 1 Combination Recruiting Advanced Solid Tumors|Lymphoma Phase 1 Alone Completed

Erdafitinib

INN name:	Erdafitinib
Lab codes:	JNJ-42756493
Chemical name:	N1-(3,5-dimethoxyphenyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N2-(propan-2-yl)ethane-1,2-diamine
Molecular formula:	C25H30N6O2
Chemical Structure:
CAS Registry Number:	1346242-81-6
Originator:	Astex Therapeutics
Developer:	Janssen Research & Development
Class:	Antineoplastics
Mechanism of Action:	Fibroblast growth factor receptor antagonists
WHO ATC code:	L01 (Antineoplastic Agents)
EPhMRA code:	L1 (Antineoplastics)
Clinical Trials: Conditions Phases Status Urothelial Cancer Phase 2 Recruiting Tumor or Lymphoma Phase 1 Recruiting Neoplasms;   Lymphoma;   Adenocarcinoma;   Esophagogastric Junction Phase 1 Recruiting Carcinoma, Hepatocellular Phase 1 Recruiting
Recent activities on the drug: